A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in…
Just two months after it first floated on the ASX, ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV).